- Home
- / Sawai Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sawai Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
¥187.2 B
FY, 2021
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
| Revenue | 168.1B | 184.3B | 182.5B | 187.2B |
| Cost of goods sold | 88.6B | 98.3B | 91.1B | 96.5B |
| Gross profit | 79.4B | 86.0B | 91.7B | 91.1B |
| Gross profit margin, % | 47.3% | 46.7% | 50.2% | 48.6% |
| Operating expense total | 43.0B | 43.9B | 46.9B | 53.9B |
| Depreciation and amortization | 14.2B | 16.3B | 18.0B | 18.3B |
| EBITDA | 36.4B | 42.1B | 44.7B | 37.2B |
| EBITDA margin, % | 21.7% | 22.9% | 24.5% | 19.9% |
| EBIT | 21.8B | 25.5B | 26.8B | 18.9B |
| EBIT margin, % | 13.0% | 13.8% | 14.7% | 10.1% |
| Interest income | 51.0M | 196.0M | 157.0M | 6.0M |
| Interest expense | 1.0B | 529.0M | 558.0M | 566.0M |
| Pre tax profit | 20.3B | 25.7B | 26.5B | 18.5B |
| Income tax expense | 6.1B | 5.9B | 6.7B | 7.6B |
| Net Income | 14.1B | 19.7B | 19.8B | 10.9B |